Ann Palliat Med:自体软骨和硅胶假体隆鼻的疗效和并发症发生率有多大差别?

2022-07-01 医路坦克 MedSci原创

鼻整形术是一种整形外科手术,可以使用各种假体材料来雕刻或抬高鼻子以美化其形状,本文全面分析和比较了使用自体软骨(AC)和硅胶材料进行隆鼻手术的疗效和并发症发生率。

鼻整形术是一种整形外科手术,可以使用各种假体材料来雕刻或抬高鼻子以美化其形状,它是整形美容外科最常见的手术之一。传统的隆鼻手术是通过人工假体实现的,其材料包括硅胶、膨体聚四氟乙烯(ePTFE)和羟基磷灰石。

固体硅胶鼻假体是由高温硫化形成的固体聚合物,具有一定的弹性和硬度。有 "L "形和柳叶形固体硅胶假体,操作简单方便,价格相对低廉。此外,可以根据患者的鼻部雕塑制作个性化的假体,术后形态自然逼真。然而,固体硅胶置入部位存在变形和感染等并发症,研究统计,单纯使用硅胶假体(SP)的隆鼻手术并发症高达17%。

自体骨组织是另一种常用的隆鼻材料,其优点是移植后容易存活,无排斥反应;但也存在取材不便、长期骨吸收、形状改变等问题

固体硅胶材料和自体软骨(AC)组织都有各自的优点和缺点。在这项荟萃分析中,我们全面分析和比较了使用AC和硅胶材料进行隆鼻手术的疗效和并发症发生率。

方法通过关键词的快速匹配,检索Medline、Embase、PubMed、中国国家知识基础设施(CNKI)和万方等数据库,获得与AC隆鼻或硅胶填充隆鼻相关的随机对照试验,经筛选和质量评估后用Stata16.0软件进行分析。

结果本研究共纳入了7篇文章中的1233名接受隆鼻手术的患者。Meta分析显示,使用AC的隆鼻手术会获得更多的满意度[风险比(RR)=1.11;95%置信区间(CI):(1.02,1.21);Z=2.413;P=0.016]。 会降低并发症率[RR=0。 34; 95% CI: (0.22, 0.52); Z=-5.010; P<0.0001],与硅胶假体(SP)材料相比,二次手术率[RR =0.34; 95% CI: (0.18, 0.64); Z=-3.363; P=0.001]。

纳入文献的基本特征、参与者特征及质量评价得分

AC材料与SP材料的总体满意率比较。CI,置信区间

AC材料与SP材料鼻整形术的总体并发症发生率。CI,置信区间

AC材料与SP材料鼻成形术的二次手术率比较(10,12,14)。CI,置信区间

结论:在隆鼻手术中,使用AC材料可以获得更多的满意度,总的并发症率较低,而且二次手术率也比硅胶材料低。但基于研究中的异质性和发表偏倚,这一论点仍需通过纳入更多高质量的研究来进一步探讨。

文献来源:Wu C,  Yang S,  Zheng G,  A systematic review and meta-analysis of the efficacy and complication rates of augmentation rhinoplasty with autologous cartilage and silicone prosthesis.Ann Palliat Med 2022 Mar;11(3)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1758451, encodeId=fa381e5845133, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 01 05:23:35 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826807, encodeId=f343182680e97, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Aug 11 08:23:35 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329628, encodeId=96ba132962817, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468371, encodeId=d69014683e1a6, content=<a href='/topic/show?id=2d3d2e5176a' target=_blank style='color:#2F92EE;'>#假体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27517, encryptionId=2d3d2e5176a, topicName=假体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b576903125, createdName=lanyan20020088, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611639, encodeId=03a71611639db, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1758451, encodeId=fa381e5845133, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 01 05:23:35 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826807, encodeId=f343182680e97, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Aug 11 08:23:35 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329628, encodeId=96ba132962817, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468371, encodeId=d69014683e1a6, content=<a href='/topic/show?id=2d3d2e5176a' target=_blank style='color:#2F92EE;'>#假体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27517, encryptionId=2d3d2e5176a, topicName=假体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b576903125, createdName=lanyan20020088, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611639, encodeId=03a71611639db, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1758451, encodeId=fa381e5845133, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 01 05:23:35 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826807, encodeId=f343182680e97, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Aug 11 08:23:35 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329628, encodeId=96ba132962817, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468371, encodeId=d69014683e1a6, content=<a href='/topic/show?id=2d3d2e5176a' target=_blank style='color:#2F92EE;'>#假体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27517, encryptionId=2d3d2e5176a, topicName=假体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b576903125, createdName=lanyan20020088, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611639, encodeId=03a71611639db, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=)]
    2022-06-26 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1758451, encodeId=fa381e5845133, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 01 05:23:35 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826807, encodeId=f343182680e97, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Aug 11 08:23:35 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329628, encodeId=96ba132962817, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468371, encodeId=d69014683e1a6, content=<a href='/topic/show?id=2d3d2e5176a' target=_blank style='color:#2F92EE;'>#假体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27517, encryptionId=2d3d2e5176a, topicName=假体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b576903125, createdName=lanyan20020088, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611639, encodeId=03a71611639db, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1758451, encodeId=fa381e5845133, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 01 05:23:35 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826807, encodeId=f343182680e97, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Aug 11 08:23:35 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329628, encodeId=96ba132962817, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468371, encodeId=d69014683e1a6, content=<a href='/topic/show?id=2d3d2e5176a' target=_blank style='color:#2F92EE;'>#假体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27517, encryptionId=2d3d2e5176a, topicName=假体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b576903125, createdName=lanyan20020088, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611639, encodeId=03a71611639db, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 26 15:23:35 CST 2022, time=2022-06-26, status=1, ipAttribution=)]

相关资讯

明明患的是心脏病,为何偏瘫了?

心房颤动是最常见的持续性心律失常。随着年龄增长,房颤的发生率不断增加,75岁以上人群可达10%。

Diabetologia:糖尿病患者全因死亡率和未来并发症的种族差异

与健康人相比,糖尿病患者的寿命缩短,直接归因于高血糖、过量NEFA和胰岛素抵抗导致的大血管(包括冠状动脉疾病、外周动脉疾病和中风)和微血管(神经病变、肾病和视网膜病变)并发症的发展。

Front Med :新型预测模型分析新发银屑病关节炎患者的相关并发症研究

银屑病是一种慢性皮肤病,在发达国家影响 2-3% 的普通人群。本前瞻性研究的目的是确定与疾病和患者相关的特征,这些特征可以预测新发 PsA 中更高的“即时”严重程度。

老年高血压的5大特点!常与多种疾病并存,并发症多......

随着我国老龄化社会进程的加快,超过一半的老年人患有高血压,在大于80岁的高龄老年人群中,高血压的患病率接近90%。高血压是罹患脑卒中、心肌梗死乃至造成心脑血管死亡的首要独立危险因素。

Int J Urol:机器人辅助根治性膀胱切除术后并发症的预测因素

评价了机器人辅助根治性膀胱切除术后的并发症,并揭示了是否存在术后并发症的预测因素。

DCR:术前营养评分可以作为 II 至 III 期结直肠癌患者总生存期和术后并发症的预测指标

术前营养和炎症状态与术后患者的疾病结果息息相关,国际癌症控制联盟 (UICC) 在肿瘤淋巴结转移 (TNM) 分类中将营养状况和炎症评分列为食管癌、肝细胞癌的危险因素。